Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
· seekingalpha.com
Ultragenyx (RARE) outlook: 2026 revenue guidance, cost controls, and key FDA/PDUFA catalysts (DTX401, UX111, GTX-102).
My bullish view on Ultragenyx ( RARE ) is not based on pretending the company has avoided disappointment. The company's failed Phase 3 readout for setrusumab (o...